Home > Boards > US Listed > Medical - Drugs > Antares Pharma, Inc. (ATRS)

SOS on ATRS: Projections

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
H2R Member Profile
 
Followed By 18
Posts 1,526
Boards Moderated 0
Alias Born 07/17/14
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/21/2020 6:29:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/21/2020 6:28:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/21/2020 6:24:52 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 1:19:20 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/11/2020 7:08:02 AM
Antares Pharma Announces Full-Year 2020 Net Revenue Guidance Range of $135 to $155 Million GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award GlobeNewswire Inc. - 12/6/2019 7:00:10 AM
Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire Inc. - 11/27/2019 5:51:22 PM
Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd. GlobeNewswire Inc. - 11/19/2019 7:00:00 AM
Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd. GlobeNewswire Inc. - 11/19/2019 1:00:00 AM
Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire Inc. - 11/13/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 4:16:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 7:31:28 AM
Antares Pharma Reports Third Quarter 2019 Operating and Financial Results GlobeNewswire Inc. - 11/5/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/4/2019 7:02:13 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/4/2019 7:00:22 AM
Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet™ Needle-Free Delivery System GlobeNewswire Inc. - 10/31/2019 7:00:05 AM
Antares Pharma to Report Third Quarter 2019 Financial and Operating Results GlobeNewswire Inc. - 10/29/2019 7:00:05 AM
Gazit Globe Offer to Acquire All Minority Shareholder Interests in Subsidiary Atrium Has Not Been Approved GlobeNewswire Inc. - 10/25/2019 10:41:10 AM
Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting GlobeNewswire Inc. - 10/24/2019 7:00:05 AM
Gazit Globe Reaffirms its Commitment and Price GlobeNewswire Inc. - 10/11/2019 2:41:57 PM
Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/17/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2019 5:01:34 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:02:45 PM
H2R   Tuesday, 11/19/19 03:47:26 PM
Re: None
Post # of 4751 
SOS on ATRS: Projections


https://smithonstocks.com/antares-pharmaceuticals-projecting-very-strong-growth-in-xyosted-sales-for-2020-2021-and-2022-atrs-buy-3-89/

Quote:

Key Points

In my sales and earnings model for 2020, I will be using a working estimate of $53.6 million for sales of Xyosted in 2020.

My working estimate is lower than two alternative scenarios laid out in this report. In Scenario 1, I arrive at a sales estimate of $70.3 million for 2020 and in scenario 2 it is $63.1 million.

My intuition is that the assumptions underlying both Scenarios 1 and 2 are conservative. However, we are at a very early stage in the launch and have only sketchy data so that I have “haircut” my working estimate to $53.6 million.

Quite recently, the consensus Street estimate for 2020 sales was $45 to $50 million.

My working estimate for 2021 sales is $85.8 million and for 2022 is $115.8 million.



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist